Journal of Internal Medicine Concepts & Practice >

2021 , Vol. 16 >Issue 06: 409 - 412

DOI: https://doi.org/10.16138/j.1673-6087.2021.06.008

Original article

Impact of preadmission anticoagulation adherent to guidelines on prognosis of the patients with atrial fibrillation

Expand
  • 1. Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
    2. Qinhuangdao Center for Disease Control and Prevention, Qinhuangdao 066000, China

Received date: 2021-05-18

  Online published: 2022-07-25

Fold

Abstract

Objective To explore the risk of all-cause death, stroke, and bleeding in the atrial fibrillation(AF) patients with or without recommended anticoagulation preadmitting to hospital. Methods A total of 5 526 hospitalized AF patients in our hospital from September 2008 to December 2018 were enrolled and their information were analyzed retrospectively. The outcomes were confirmed according to hospitalization records, course records and discharge diagnosis, including all bleeding events, major bleeding, minor bleeding, gastric bleeding, stroke and death. Univariate and multivariate Logistic regression analysis was performed to explore the risk of end events during hospitalization. Results The patients with recommended anticoagulation（1 480, 22.78%） had lower risk of stroke [odds ratio (OR)=0.68, 95% confidence interval (CI): 0.50-0.92, P=0.01]. They had similar risk in all bleeding events, major bleeding, minor bleeding, gastric bleeding and all-cause death compared to those without recommended anticoagulation. Conclusions Recommended anticoagulation reduced the risk of all-cause death and stroke, but did not increase the risk of all bleeding events, major bleeding, minor bleeding, gastric bleeding and all-cause death.

Key words： Atrial fibrillation; Recommended anticoagulation; Bleeding; Stroke; All-cause death

Cite this article

BAI Ying, LIU Xinyao, ZHANG Xilin, GAO Zhaofang, SHI Xubo, DENG Kewu . Impact of preadmission anticoagulation adherent to guidelines on prognosis of the patients with atrial fibrillation[J]. Journal of Internal Medicine Concepts & Practice, 2021 , 16(06) : 409 -412 . DOI: 10.16138/j.1673-6087.2021.06.008

References

[1] Bai Y, Wang YL, Shantsila A, et al. The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia[J]. Chest, 2017, 152(4): 810-820.
[2] Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis[J]. Stroke, 2017, 48(4): 970-976.
[3] Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis[J]. Age Ageing, 2018, 47(1): 9-17.
[4] Chan PH, Lau CP, Tse HF, et al. CHA2DS2-VASc recalibration with an additional age category (50-64 years) enhances stroke risk stratification in Chinese patients with atrial fibrillation[J]. Can J Cardiol, 2016, 32(12): 1381-1387.
[5] Chang SS, Dong JZ, Ma CS, et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese atrial fibrillation registry study[J]. Stroke, 2016, 47(7): 1803-1810.
[6] Bai Y, Yue QM, Sun H, et al. Prevalence and sex- and age-related risk of pulmonary embolism in in-hospital patients with atrial fibrillation: a multicenter retrospective study from China[J]. Ann Transl Med, 2020, 8(23): 1558.
[7] Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants[J]. Thromb Haemost, 2017, 117(2): 209-218.
[8] Hess PL, Kim S, Fonarow GC, et al. Absence of oral anticoagulation and subsequent outcomes among outpatients with atrial fibrillation[J]. Am J Med, 2017, 130(4): 449-456.
[9] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007, 146(12): 857-867.
[10] Liakishev AA. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial[J]. Kardiologiia, 2008, 48(2): 68.
[11] Di Giosia P, Giorgini P, Ferri C. Considerations on stroke in atrial fibrillation despite anticoagulation[J]. J Cardiovasc Med (Hagerstown), 2018, 19 Suppl 1: e54-e57.
[12] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace, 2016, 18(11): 1609-1678.
[13] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21): e1-e76.
[14] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey[J]. Chest, 2010, 138(5): 1093-1100.
Options
Outlines

/

〈 〉